ADXS insider filings
Ayala Pharmaceuticals, Inc. — 11 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-03-06. Screen ADXS transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for ADXS between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Ayala Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-03-06 | 4 | Israel Biotech Fund I, L.P. — Director, 10% owner Israel Biotech Fund II, L.P. — Director, 10% owner Israel Biotech Fund GP Partners, L.P. — Director, 10% owner Israel Biotech Fund GP Partners II, L.P. — Director, 10% owner I.B.F. Management Ltd. — Director, 10% owner | Option exercise (M): 3,750,000 (derivative) · Option exercise (M): 3,750,000 (derivative) · Option exercise (M): 1,500,000 (derivative) · Option exercise (M): 1,500,000 (derivative) · Option exercise (M): 2,250,000 (derivative) · Option exercise (M): 2,250,000 (derivative) | EDGAR |
| 2024-02-12 | 4 | Israel Biotech Fund I, L.P. — Director, 10% owner Israel Biotech Fund II, L.P. — Director, 10% owner Israel Biotech Fund GP Partners, L.P. — Director, 10% owner Israel Biotech Fund GP Partners II, L.P. — Director, 10% owner I.B.F. Management Ltd. — Director, 10% owner | Option exercise (M): 1,926,221 @ $0.40 · Option exercise (M): 4,237,687 @ $0.40 · Option exercise (M): 3,887,438 @ $0.40 · Option exercise (M): 1,295,813 @ $0.40 · Option exercise (M): 8,437,500 @ $0.40 · Tax withholding (F): 2,707,581 @ $1.25 · +8 more | EDGAR |
| 2023-11-21 | 4 | Israel Biotech Fund I, L.P. — 10% owner Israel Biotech Fund II, L.P. — 10% owner Israel Biotech Fund GP Partners, L.P. — 10% owner Israel Biotech Fund GP Partners II, L.P. — 10% owner I.B.F. Management Ltd. — 10% owner | Purchase (P) · Purchase (P) · Purchase (P): 2,812,500 (derivative) · Purchase (P): 6,187,500 (derivative) · Purchase (P): 5,625,000 (derivative) · Purchase (P): 6,187,500 (derivative) · +4 more | EDGAR |
| 2023-10-31 | 4 | Israel Biotech Fund I, L.P. — 10% owner Israel Biotech Fund II, L.P. — 10% owner Israel Biotech Fund GP Partners, L.P. — 10% owner Israel Biotech Fund GP Partners II, L.P. — 10% owner I.B.F. Management Ltd. — 10% owner | Purchase (P): 658,858 @ $0 · Purchase (P): 658,858 @ $0 | EDGAR |
| 2023-10-23 | 4 | aMoon Growth Fund Limited Partnership — 10% owner | Other (J): 0 @ $0 | EDGAR |
| 2023-09-29 | 4/A | Israel Biotech Fund I, L.P. — 10% owner Israel Biotech Fund II, L.P. — 10% owner Israel Biotech Fund GP Partners, L.P. — 10% owner Israel Biotech Fund GP Partners II, L.P. — 10% owner I.B.F. Management Ltd. — 10% owner | Purchase (P) @ $1,500,000 · Purchase (P) @ $500,000 | EDGAR |
| 2023-09-11 | 4 | Israel Biotech Fund I, L.P. — 10% owner Israel Biotech Fund II, L.P. — 10% owner | Purchase (P) @ $1,500,000 · Purchase (P) @ $500,000 | EDGAR |
| 2023-01-23 | 4 | SIDRANSKY DAVID — Director | Grant/award (A): 46 · Grant/award (A): 2,342 (derivative) · Grant/award (A): 2,342 (derivative) | EDGAR |
| 2023-01-23 | 4 | GOLDBERG MURRAY A — Director | Grant/award (A): 3,279 (derivative) · Grant/award (A): 2,342 (derivative) · Grant/award (A): 1,171 (derivative) · Grant/award (A): 1,171 (derivative) | EDGAR |
| 2023-01-23 | 4 | Bisker-Leib Vered — Director | Grant/award (A): 1,639 (derivative) · Grant/award (A): 1,171 (derivative) · Grant/award (A): 1,171 (derivative) | EDGAR |
| 2023-01-23 | 4 | Spiegel Robert J. — Director | Grant/award (A): 3,279 (derivative) · Grant/award (A): 2,342 (derivative) · Grant/award (A): 1,171 (derivative) · Grant/award (A): 1,171 (derivative) | EDGAR |
Recent 8-K events — Ayala Pharmaceuticals, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2024-04-19 | 8-K/A | 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-04-03 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2024-03-29 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-03-05 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-02-23 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-02-09 | 8-K | 3.02 — Unregistered Sales of Equity Securities 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-02-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-01-03 | 8-K/A | 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-10-20 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.02 — Unregistered Sales of Equity Securities 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-09-21 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ADXS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs